HC Wainwright Brokers Increase Earnings Estimates for VTVT

vTv Therapeutics Inc. (NASDAQ:VTVT) – Stock analysts at HC Wainwright lifted their Q1 2026 EPS estimates for vTv Therapeutics in a note issued to investors on Wednesday, March 11th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn $0.99 per share for the quarter, up from their prior estimate of $0.96. HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock.

Several other brokerages also recently commented on VTVT. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. BTIG Research reiterated a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research note on Wednesday. Roth Mkm began coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 price target on the stock. Finally, Evercore started coverage on shares of vTv Therapeutics in a research report on Thursday. They set an “outperform” rating and a $44.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Trading Down 4.0%

NASDAQ VTVT opened at $33.71 on Thursday. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The stock’s fifty day moving average price is $36.06 and its 200-day moving average price is $29.29. The stock has a market cap of $132.82 million, a P/E ratio of -10.06 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.51. The company had revenue of ($0.02) million during the quarter.

Institutional Trading of vTv Therapeutics

Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics in the fourth quarter worth approximately $221,000. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the 4th quarter valued at $731,000. Geode Capital Management LLC lifted its holdings in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after buying an additional 12,896 shares during the period. Finally, Baker BROS. Advisors LP lifted its holdings in shares of vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the period. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.